Acute effects of GLP-1 on glucose uptake in obese subjects

体外研究表明，GLP-1是 脂肪和肌肉中都有轻微的胰岛素分泌。我们在美国做了一项研究 非肥胖(即非胰岛素抵抗)受试者(发表于J.Clin。 内分泌激素。Metab，1998年7月)静脉注射GLP-1，并可能 不能说明这一现象。然而，由于受试者已经 正常的胰岛素作用我们可能不能表现出微妙的 模仿胰岛素的行为。因此，我们启动了一项关于肥胖的研究， 非糖尿病(胰岛素抵抗，血糖正常)受试者 看看GLP-1是否会减少胰岛素抵抗。这将会 也告诉我们，GLP-1类化合物是否不仅对 糖尿病，但也在葡萄糖不耐受。以下是治疗选项 目前可用于2型糖尿病的药物还不够完善。浩瀚无边 大多数2型糖尿病患者在某些情况下需要胰岛素 他们的生活是因为不断恶化的β细胞功能。项目 编号Z01AG00214-07的LCP表明，连续的GLP-1 治疗可改善糖耐量，增加β细胞比率 啮齿动物的细胞周转。GLP-1，皮下注射给人类 在每顿饭之前，确实能降低血糖。但血糖水平 在下一次药丸之前再次上涨。我们想看看GLP-1是否给了 持续的皮下注射将正常化并维持 血糖正常。因此，我们启动了一项研究， GLP-1通过迷你医用泵持续皮下给药 (一个寻呼机大小的小泵)到2型糖尿病 受试者48小时。然后我们研究胰岛素分泌。 容量和胰岛素敏感性。这些研究正在进行中。

Research done in vitro has shown that GLP-1 is mildly insulinomimetic in both fat and muscle. We did a study in non- obese (ie, not insulin resistant) subjects (published J. Clin. Endocrinol. Metab, July 1998) with intravenous GLP-1 and could not demonstrate this phenomenon. However, as the subjects had normal insulin action we may not have been able to show subtle insulinomimetic actions. We therefore initiated a study in obese, non diabetic (insulin resistant, with normal blood glucose) subjects to see if GLP-1 would decrease resistance to insulin. This would also tell us if a GLP 1-like compound might not only be useful in diabetes, but also in glucose intolerance. Treatment options that are presently available for type 2 diabetes are less than perfect. The vast majority of type 2 diabetic subjects require insulin at some point in their lives because of deteriorating beta cell function. Project Number Z01AG00214-07 LCP has shown that continuous GLP-1 treatment improves glucose tolerance and increases the rate of beta cell turnover in rodents. GLP-1, given subcutaneously to humans before each meal, does lower blood sugar. But blood sugar levels rise again before the next bolus. We wished to see if GLP-1 given continuously subcutaneously would normalize and maintain a normal blood sugar. We have, therefore, initiated a study whereby GLP-1 is given continuously subcutaneously, via a Mini-Med pump (a small pump about the size of a beeper) to Type 2 diabetic subjects for 48 hours. We then investigate for insulin-secretory capacity and insulin sensitivity. These studies are on-going.